Haemonetics Revenue
The The revenue of Haemonetics (HAE) as of Nov 4, 2026 is 1.33 B USD. In the previous year, The revenue was 1.36 B USD — a change of -1.97% (lower).
Get this data via API
Financial Data API
Revenue
1.33 BUSD
YoY
-1.97%
Last updated:
In 2026, Haemonetics's sales reached 1.33 B USD, a -1.97% difference from the 1.36 B USD sales recorded in the previous year.
Over the last 19 years Haemonetics grew revenue by 5.9% annually, reaching 1.33 B USD.
The Haemonetics Revenue history
3 Years
10 Years
25 Years
Max
| YEAR | Revenue | YoY |
|---|---|---|
| est | 1.83 BUSD | +12.95% |
| est | 1.62 BUSD | +8.21% |
| est | 1.50 BUSD | +5.48% |
| est | 1.42 BUSD | +6.27% |
| 1.33 BUSD | -1.97% | |
| 1.36 BUSD | +3.95% | |
| 1.31 BUSD | +12.01% | |
| 1.17 BUSD | +17.67% | |
| 993.20 MUSD | +14.10% | |
| 870.46 MUSD | -11.94% | |
| 988.48 MUSD | +2.16% | |
| 967.58 MUSD | +7.04% | |
| 903.92 MUSD | +2.01% | |
| 886.12 MUSD | -2.50% | |
| 908.83 MUSD | -0.17% | |
| 910.37 MUSD | -3.00% | |
| 938.51 MUSD | +5.22% | |
| 891.99 MUSD | +22.55% | |
| 727.84 MUSD | +7.56% | |
| 676.69 MUSD | +4.84% | |
| 645.43 MUSD | +7.95% | |
| 597.88 MUSD | +15.77% | |
| 516.44 MUSD | +14.86% | |
| 449.61 MUSD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Haemonetics Revenue
Haemonetics Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Haemonetics Margins
Haemonetics stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Haemonetics Stock analysis
Revenue Details
Understanding Haemonetics's Sales Figures
The sales figures of Haemonetics originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Haemonetics’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Haemonetics's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Haemonetics’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Haemonetics stock
The revenue of Haemonetics is 1.33 B USD in 2026.
The revenue of Haemonetics changed from 1.36 B USD to 1.33 B USD, representing a -1.97% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of The revenue Haemonetics since 2006 – with annual values, charts, and detailed analysis.
Revenue is the total value of all goods sold in a period. It is calculated by multiplying the quantity of each product sold by its selling price. Revenue does not include any costs (material costs, personnel costs, etc.), whereas net proceeds only deduct revenue reductions associated with the sale (discounts, etc.).
The revenue's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The revenue's Haemonetics historically and in real time.
The revenue in assessing a stock
Revenue is an important financial measure used in the valuation of stocks. It is a measure of a company's economic activity and can serve as an indicator of the company's success. Revenue is considered one of the most important factors in stock valuation. In addition, revenue can also be used to calculate other financial measures such as earnings per share and price-earnings ratio.
History and utilization of revenue
Revenue has long been considered one of the most important financial indicators. It was used in the 19th century as one of the first financial indicators to measure a company's economic activity. Since then, revenue has been regularly used to evaluate companies.
Revenue is usually calculated as a percentage of the company's equity. It can also be used to determine the overall profitability of a company. There are many different types of revenue that can be used to measure a company's economic activity, such as gross revenue, net revenue, and revenue from international business.
The revenue can also be used to evaluate stocks. For example, the revenue of a company can be used to evaluate the success of the company. If a company has high revenue, it means that it is a profitable company because it has high demand for its products or services.
Calculation and Application of Revenue
In order to calculate a company's revenue, the company's income must be deducted from its expenses. The income can come from various sources, such as sales, licensing fees, services, etc. The expenses can include costs for production, procurement, inventory, sales, and administration.
The revenue can then be used to calculate various financial ratios. For example, the revenue can be used to calculate the price-earnings ratio (P/E ratio) of a company. This is a measure of a company's profitability, calculated by taking the ratio of the stock price to earnings per share.
Revenue can also be used to calculate earnings per share (EPS) of a company. This is a measure of a company's profit per share. EPS is calculated by dividing earnings by the number of shares issued.
Use of revenue by investors
Investors use revenue to evaluate stocks, as revenue is an indicator of a company's success. For example, an investor can compare a company's revenue to see how successful it is. An investor can also use a company's revenue to calculate its price-to-earnings ratio and earnings per share.
An example: An investor looks at a company that has a revenue of 25 million euros. He compares this revenue to that of the competitor, which has a revenue of 35 million euros. The investor can then see that the company with 25 million euros in revenue is less successful than the company with 35 million euros in revenue.
Advantages and Disadvantages of Revenue.
Revenue is a very useful tool for valuing stocks as it measures a company's economic activity. Revenue can also be used to calculate other financial ratios such as the price-earnings ratio and earnings per share.
However, one disadvantage is that revenue alone is not a meaningful indicator of a company's success. It is important to consider revenue in comparison to other financial metrics such as earnings per share and price-to-earnings ratio to get a complete picture of the company.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Income Statement — Haemonetics
All Key Metrics — Haemonetics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth